Jun. 9, 2010
According to a report in the 21st Century Business Herald of June 10, 2010, China’s State Food and Drug Administration (SFDA) is to nullify the current Rx/OTC dual status of drugs. The report quoted sources from the China Nonprescription Medicines Association (CNMA) and undisclosed drug firms.
The Rx/OTC dual status refers to drugs that exist as both prescription and over-the-counter medicines. There are currently more than 2300 drugs with Rx/OTC dual status in China.